MyJournals Home  

RSS FeedsInactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors (Oncogene)

 
 

20 september 2019 17:00:26

 
Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors (Oncogene)
 




 
171 viewsCategory: Oncology
 
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer (British Journal of Cancer)
Heat-shock proteins: chaperoning DNA repair (Oncogene)
 
 
blog comments powered by Disqus


MyJournals.org
The latest issues of all your favorite science journals on one page

Username:
Password:

Register | Retrieve

Search:

Oncology


Copyright © 2008 - 2024 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures News Tweets Nachrichten